Precigen, Inc. (PGEN) Financial Ratios
15 years of historical data (2011–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
30Y Low144.6·High144.6
P/B Ratio
↑
70.24
↑+335% vs avg
5yr avg: 16.14
30Y Low2.2·High60.9
ROE
↓
-843.6%
↑-262% vs avg
5yr avg: -232.8%
30Y Low-246%·High24%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
PGEN Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Precigen, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.4B | $1.3B | $300M | $328M | $305M | $734M | $1.7B | $845M | $847M | $1.4B | $2.8B |
| Enterprise Value | $1.4B | $1.2B | $276M | $327M | $351M | $887M | $1.8B | $1.0B | $957M | $1.3B | $2.8B |
| P/E Ratio → | -3.42 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 149.53 | 131.52 | 76.40 | 52.64 | 11.32 | 51.43 | 53.27 | 26.40 | 5.28 | 5.98 | 14.86 |
| P/B Ratio | 70.24 | 60.91 | 7.79 | 2.77 | 2.41 | 6.83 | 25.37 | 11.78 | 2.24 | 2.53 | 4.99 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
PGEN EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 128.93 | 70.28 | 52.56 | 13.05 | 62.20 | 57.34 | 31.62 | 5.96 | 5.73 | 14.58 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
PGEN Profitability
Margins and return-on-capital ratios measuring operating efficiency
Precigen, Inc. earns an operating margin of -1100.8%. Operating margins have expanded from -1602.5% to -1100.8% over the past 3 years, signaling improving operational efficiency. A negative ROE of -843.6% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 37.1% | 37.1% | -8.7% | 1.7% | 76.4% | -276.2% | -40.0% | 83.2% | 60.6% | 72.8% | 67.7% |
| Operating Margin | -1100.8% | -1100.8% | -3440.2% | -1602.5% | -281.4% | -644.5% | -269.8% | -269.8% | -314.9% | -59.7% | -65.6% |
| Net Profit Margin | -2588.2% | -2588.2% | -3216.2% | -1540.6% | 105.2% | -646.0% | -533.0% | -533.0% | -317.2% | -50.7% | -97.7% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -843.6% | -843.6% | -160.8% | -78.4% | 24.2% | -105.6% | -245.6% | -75.7% | -110.1% | -21.0% | -29.3% |
| ROA | -166.1% | -166.1% | -85.2% | -52.3% | 9.8% | -27.3% | -44.3% | -29.1% | -65.2% | -13.0% | -19.3% |
| ROIC | -1553.8% | -1553.8% | -152.8% | -51.5% | -26.2% | -30.1% | -29.7% | -17.8% | -77.8% | -20.6% | -17.2% |
| ROCE | -87.7% | -87.7% | -107.2% | -75.2% | -32.7% | -30.8% | -28.5% | -17.5% | -71.1% | -17.0% | -14.2% |
PGEN Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $30M exceeds total debt of $5M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.24 | 0.24 | 0.14 | 0.06 | 0.41 | 1.77 | 2.71 | 3.24 | 0.56 | 0.02 | 0.02 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.20 | -0.62 | -0.00 | 0.37 | 1.43 | 1.94 | 2.33 | 0.29 | -0.11 | -0.09 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -27.57 | -27.57 | -21337.00 | -204.90 | -10.80 | -4.87 | -4.65 | -4.74 | -45.42 | -211.27 | -224.49 |
Net cash position: cash ($30M) exceeds total debt ($5M)
PGEN Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Precigen, Inc.'s current ratio of 3.09x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 2.99x to 3.09x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.09 | 3.09 | 4.76 | 2.99 | 1.50 | 4.52 | 3.54 | 1.91 | 4.64 | 1.92 | 3.33 |
| Quick Ratio | 2.83 | 2.83 | 4.76 | 2.99 | 1.50 | 4.51 | 3.27 | 1.78 | 4.29 | 1.67 | 3.11 |
| Cash Ratio | 2.62 | 2.62 | 4.55 | 2.73 | 0.71 | 3.14 | 2.38 | 0.61 | 3.62 | 0.99 | 2.51 |
| Asset Turnover | — | 0.06 | 0.03 | 0.04 | 0.12 | 0.04 | 0.10 | 0.07 | 0.22 | 0.27 | 0.20 |
| Inventory Turnover | 0.64 | 0.64 | — | — | 22.09 | 164.66 | 3.94 | 0.33 | 2.95 | 3.06 | 2.92 |
| Days Sales Outstanding | — | 164.41 | 108.15 | 92.35 | 187.24 | 50.66 | 233.05 | 299.17 | 60.38 | 62.96 | 81.22 |
PGEN Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Precigen, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $305M | $268M | $245M | $200M | $198M | $167M | $154M | $130M | $120M | $118M |
Peer Comparison
Compare PGEN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 PGENYou | $1B | -3.4 | — | — | 37.1% | -1100.8% | -843.6% | -1553.8% | — |
 FATE | $244M | -1.8 | — | — | -94.1% | -2222.4% | -51.8% | -36.5% | — |
 SNDX | $2B | -5.8 | — | — | 96.0% | -158.4% | -161.8% | -54.2% | — |
 AGEN | $125M | -882.4 | — | — | 29.6% | -18.0% | — | — | — |
 CRIS | $82M | -0.7 | — | — | 99.5% | -348.4% | -138.8% | — | — |
 IMVT | $7B | -12.8 | — | — | — | — | -64.8% | — | — |
 CRSP | $5B | -8.4 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 BEAM | $4B | -42.1 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 NTLA | $2B | -4.1 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 EDIT | $263M | -1.5 | — | — | 100.0% | -245.2% | -198.1% | — | — |
 ILMN | $25B | 29.7 | 22.7 | 26.4 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 15 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
PGEN — Frequently Asked Questions
Quick answers to the most common questions about buying PGEN stock.
What is Precigen, Inc.'s P/E ratio?
Precigen, Inc.'s current P/E ratio is -3.4x. This places it at the 50th percentile of its historical range.
What is Precigen, Inc.'s ROE?
Precigen, Inc.'s return on equity (ROE) is -843.6%. The historical average is -80.7%.
Is PGEN stock overvalued?
Based on historical data, Precigen, Inc. is trading at a P/E of -3.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Precigen, Inc.'s profit margins?
Precigen, Inc. has 37.1% gross margin and -1100.8% operating margin.